^131I—C50放射免疫显像诊断卵巢癌

目的 探讨卵巢癌放免显像在卵巢癌诊断和治疗方面的临床价值。方法 采用氯胺T法制备^131I-CEA McAb(C50)，以静脉滴注方式给药，于不同时间对患者进行显像。结果 经手术和病理检查证实的105例卵巢癌患者中96例显像阳性，9例阴性（假阴性）；23例良性病灶中22例获阴性显像结果，并经手术证实。96例阳性显像中87例放射免疫显像分期与手术分期完全相符。151处转移灶发现141处，阳性率93．4％，最小检出病灶直径1cm。结论 卵巢癌放免显像对卵巢癌的早期发现，指导临床分期和制定治疗方案、预计预后有较高的临床价值。

Radioimmunoimaging of ovarian cancer with ~(131) I labeled CEA monoclonal antibody

Objective To investigate radioimmunoimaging with 131 I labeled CEA McAb and its value in diagnosis and treatment of ovarian cancer. Methods CEA McAb was labeled with 131 I by standard chloramine T procedure. The radiolabeled McAb was given intravenously to the patients. The scintigraphy was performed at different time. Results In 105 patients with histopathology proved ovarian cancers, for 96 patients the lesions were well located with RII (true positives),for the remaining 9 patients,the results were false negative. 22/23 cases with RII diagnosed benign ovarian tumors were proved to be true negative by surgical pathology in RII.Of 96 ovarian cancers 87 were stratified into identical stages by surgical pathology and RII. 141/151 metastatic tumors were found in RII and the positive rate was as high as 93.4%. The smallest tumor defected by RII was of 1 cm in diameter. Conclusions RII is as good as ultrasonography and CT in distinguishing benignancy and malignancy. The location, size and number of the lesions can also be determined with RII. RII of ovarian cancer with 131 I CEA McAb is valuable and helpful in early detection of ovarian cancer. It is also helpful for clinical staging,treatment programing and prognosticating.